Search

Your search keyword '"Afrough, Aimaz"' showing total 26 results
Start Over Author "Afrough, Aimaz" Journal transplantation and cellular therapy
26 results on '"Afrough, Aimaz"'

1. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience

Author

Khouri, Jack, Dima, Danai, Li, Hong, Hansen, Doris, Sidana, Surbhi, Shune, Leyla, Anwer, Faiz, Sborov, Douglas, Wagner, Charlotte, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter, Peres, Lauren, Hovanky, Vanna, Simmons, Gary, Williams, Louis, Raza, Shahzad, Afrough, Aimaz, Anderson, Larry D., Jr, Ferreri, Christopher, Hashmi, Hamza, Davis, James, McGuirk, Joseph, Goldsmith, Scott, Borogovac, Azra, Lin, Yi, Midha, Shonali, Nadeem, Omar, Locke, Frederick L., Baz, Rachid, Hamilton, Betty, Alsina, Melissa, Sauter, Craig, Patel, Krina, and Kaur, Gurbakhash

Published
2024
Full Text
View/download PDF

3. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Author

Varma, Ankur, Biritxinaga, Laura, Saliba, Rima M, Stich, Maximilian, Jauch, Sarah Francesca, Afrough, Aimaz, Honhar, Medhavi, Popat, Uday R, Shafi, Mehnaz A, Shah, Nina, Bashir, Qaiser, Dinh, Yvonne, Hosing, Chitra, Champlin, Richard E, and Qazilbash, Muzaffar H

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Immunology, Regenerative Medicine, Cancer, Orphan Drug, Liver Disease, Infectious Diseases, Hematology, Transplantation, Digestive Diseases, Rare Diseases, Hepatitis - B, Clinical Research, Chronic Liver Disease and Cirrhosis, Hepatitis, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Adult, Aged, Case-Control Studies, Female, Hematopoietic Stem Cell Transplantation, Hepatitis B Antibodies, Humans, Incidence, Male, Middle Aged, Multiple Myeloma, Retrospective Studies, Survival Analysis, Transplantation, Autologous, Virus Activation, Multiple myeloma, Reactivation, Resolved HBV infection, Reverse seroconversion, Cardiovascular medicine and haematology
Abstract

Hepatitis B core antibody (HBcAb) seropositivity has been associated with a higher rate of hepatitis B virus (HBV) reactivation after chemotherapy, even in patients who are hepatitis B surface antigen (HBsAg) negative. However, little is known about the risk of HBV reactivation after autologous hematopoietic stem cell transplantation (auto-HCT). We evaluated the incidence of HBV reactivation, liver toxicity, and survival in patients with multiple myeloma (MM) who received auto-HCT at our institution. We retrospectively identified 107 MM patients with resolved HBV infection (HBcAb positive, HBsAg negative) and 125 patients with negative HBV serology (control subjects) who were matched for age, timing of auto-HCT from diagnosis, cytogenetics, disease status at transplant, induction therapy, and preparative regimen. All patients underwent auto-HCT between 1991 and 2013. Primary endpoints were HBV reactivation, defined as HBsAg positivity or ≥10-fold increase in HBV DNA, and hepatotoxicity, as defined in the U.S. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. In the resolved HBV infection group, 52 patients (49%) were HBsAb positive and 24 (22%) had detectable HBV DNA before auto-HCT. Only 1 patient with resolved HBV infection received pre-emptive antiviral therapy with lamivudine, whereas 4 patients received lamivudine (n = 3) or tenofovir (n = 1) at reactivation after auto-HCT for a median duration of 12 months. HBV reactivation occurred in 7 of 107 patients (6.5%) in the resolved HBV group. Median time to HBV reactivation from auto-HCT was 16 months. The cumulative incidence of grade 2 or greater hepatotoxicity was 30% in the resolved HBV infection group and 22% in the control group (hazard ratio, 1.3; 95% confidence interval, .7 to 2.3; P = .4). Nonrelapse mortality for the 2 groups was not statistically different at 2 years (P = .06), although it trended higher in the control group than in the resolved HBV infection group (8% versus 1%). The median progression-free survival (PFS) and overall survival (OS) durations in the resolved HBV infection and control groups were 21 versus 18 months (P = .5) and 53 versus 67 months (P = .2), respectively. Our data suggest that resolved HBV infection in patients undergoing auto-HCT for MM is associated with a low risk of HBV reactivation and hepatotoxicity; these complications were reversible and did not adversely affect the PFS or OS.

Published
2017

4. Assessing the Predictive Value of Pre-Lymphodepletion and Infusion Endothelial Activation and Stress Index in CD19-Directed CAR-T Therapy for B-Cell Lymphoma

Author

Upreti, Harsh Vardhan, primary, Lee, Jimmy, additional, Sannareddy, Aishwarya, additional, Reves, Heather, additional, Turer, Laura, additional, Abraham, Pearl, additional, Liu, Yulun, additional, Yilmaz, Elif, additional, Wolfe, Heather, additional, Kaur, Gurbakhash, additional, Khan, Adeel, additional, Madanat, Yazan F., additional, Thiebaud, Julio Alvarenga, additional, Velarde, Alejandro Marino, additional, Collins, Robert H., additional, Chung, Stephen, additional, Geethakumari, Praveen Ramakrishnan, additional, Anderson, Larry D., additional, Awan, Farrukh T, additional, Afrough, Aimaz, additional, and Anderson, Julia Marie, additional

Published
2024
Full Text
View/download PDF

5. Outcomes in Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Author

Soomro, Mohammad Ahsen, primary, Atrash, Shebli, additional, Rashid, Aliya, additional, Wesson, William, additional, Hashmi, Mr. Hamza, additional, Afrough, Aimaz, additional, Skikne, Barry S., additional, Lutfi, Forat, additional, Mushtaq, Muhammad Umair, additional, Abdallah, Al-Ola, additional, Ahmed, Nausheen, additional, and Khaliq, Aroog, additional

Published
2024
Full Text
View/download PDF

6. Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single Center Retrospective Analysis.

Author

Sannareddy, Aishwarya, primary, Lee, Jimmy, additional, Upreti, Harsh Vardhan, additional, Turer, Laura, additional, Anderson, Julia Marie, additional, Reves, Heather, additional, Gaines, Kailee, additional, Patel, Hetalkumari, additional, Abraham, Pearl, additional, Jones, Ashley, additional, Yn, Alicia, additional, Eze, Ebubechukwu, additional, Chong, Pearlie, additional, Tessier, Jeffrey, additional, Chung, Stephen, additional, Collins, Robert H., additional, Madanat, Yazan F., additional, Wolfe, Heather, additional, Yilmaz, Elif, additional, Thiebaud, Julio Alvarenga, additional, Geethakumari, Praveen Ramakrishnan, additional, Kaur, Gurbakhash, additional, Khan, Adeel, additional, Anderson, Larry D., additional, Awan, Farrukh T, additional, La Hoz, Ricardo, additional, and Afrough, Aimaz, additional

Published
2024
Full Text
View/download PDF

7. Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel

Author

Akhtar, Othman Salim, primary, Hashmi, Hamza, additional, Oloyede, Temitope, additional, Brazauskas, Ruta, additional, Bye, Matthew, additional, Sidana, Surbhi, additional, Hansen, Doris K, additional, Ahmed, Nausheen, additional, Ferreri, Christopher, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Dhakal, Binod, additional, Dhanda, Devender, additional, Gowda, Lohith, additional, Harrison, Melanie, additional, Kitali, Amani, additional, Landau, Heather J, additional, Mirza, Abu-Sayeef, additional, Patel, Dr. Jinalben, additional, Patwardhan, Pallavi, additional, Qazilbash, Muzaffar H., additional, Patel, Krina K., additional, Nishihori, Taiga, additional, Ganguly, Siddhartha MD, additional, Pasquini, Marcelo C., additional, Usmani, Saad Z., additional, and Freeman, Ciara Louise, additional

Published
2024
Full Text
View/download PDF

8. Immune Engager Therapies Are Associated with Better Outcomes in Post Ide-Cel Relapse in MM- an Analysis of the US MM Immunotherapy Consortium Database.

Author

Janakiram, Murali, primary, Khouri, Jack, additional, Castaneda, Omar, additional, Shune, Leyla, additional, Dima, Danai, additional, Kaur, Gurbakhash, additional, De Avila, Gabe, additional, Gaballa, Mahmoud, additional, Midha, Shonali, additional, Davis, James, additional, Wagner, Charlotte, additional, McGuirk, Joseph P, additional, Forsberg, Peter, additional, Reshef, Ran, additional, Lin, Yi, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Davila, Dr. Marco L., additional, Kocoglu, Mehmet H., additional, Sborov, Douglas, additional, Htut, Myo, additional, Hashmi, Hamza, additional, Sidana, Surbhi, additional, Chowdhury, Arnab, additional, Patel, Krina K., additional, Hansen, Doris K, additional, and Atrash, Shebli, additional

Published
2024
Full Text
View/download PDF

9. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)

Author

Dima, Danai, primary, Davis, James, additional, Ahmed, Nausheen, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher Sun, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Hashmi, Hamza, additional, and Abdallah, Al-Ola, additional

Published
2024
Full Text
View/download PDF

10. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Author

Dima, Danai, primary, Davis, James A., additional, Ahmed, Nausheen, additional, Jia, Xuefei, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Abdallah, Al-Ola, additional, and Hashmi, Hamza, additional

Published
2023
Full Text
View/download PDF

11. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation

Author

Afrough, Aimaz, Pasvolsky, Oren, Ma, Junsheng, Srour, Samer, Bashir, Qaiser, Saini, Neeraj, Hosing, Chitra, Popat, Uday R., Kebriaei, Partow, Delgado, Ruby, Ullah, Muhammad R., Murphy, Regan, Manasanch, Elisabet E., Lee, Hans C., Kaufman, Gregory P., Patel, Krina K., Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., and Qazilbash, Muzaffar H.

Published
2022
Full Text
View/download PDF

12. Infectious Complications Post-CAR T-Cell Therapy for Lymphomas: Impact of Bridging Therapy

Author

Lue, Brian Ko-Hung, primary, Patel, Akshat Maneesh, additional, Reves, Heather, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Chung, Stephen, additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Kumar, Kiran, additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Awan, Farrukh T, additional, Tessier, Jeffrey M, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2023
Full Text
View/download PDF

13. Impact of Autologous Hematopoietic Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL): A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Author

Reves, Heather, primary, Jackson, Meredith, additional, Prasad, Tanushree, additional, Afrough, Aimaz, additional, Anderson, Larry D., additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Wolfe, Heather, additional, Yilmaz, Elif, additional, Khan, Adeel, additional, Kumar, Kiran, additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Awan, Farrukh T, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2023
Full Text
View/download PDF

14. ‘Real-World’ Impact of Tixagevimab/Cilgavimab (Evusheld) on COVID-19 Outcomes in Patients Undergoing Cellular Therapies

Author

Sannareddy, Aishwarya, primary, Reves, Heather, additional, Narasimhan, Madhusudhanan, additional, Jaleta, Kefyalew, additional, Anderson, Julia Marie, additional, Patel, Hetalkumari, additional, Anderson, Larry D., additional, Afrough, Aimaz, additional, Chung, Stephen, additional, Collins, Robert H., additional, Kaur, Gurbakhash, additional, Kumar, Kiran A, additional, Madanat, Yazan F., additional, Vusirikala, Madhuri, additional, Awan, Farrukh T, additional, Muthukumar, Alagar R, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2023
Full Text
View/download PDF

15. Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience

Author

Sidana, Surbhi, primary, Peres, Lauren, additional, Hashmi, Hamza, additional, Hosoya, Hitomi, additional, Ferreri, Christopher, additional, Atrash, Shebli, additional, Khouri, Jack, additional, Voorhees, Peter M., additional, Dima, Danai, additional, Simmons, Gary Lee, additional, Kalariya, Nilesh, additional, Hovanky, Vanna, additional, Bharadwaj, Sushma, additional, Arai, Sally, additional, Miklos, David B., additional, Wagner, Charlotte, additional, Davis, James, additional, Sborov, Douglas, additional, Nishihori, Taiga, additional, Alsina, Melissa, additional, Locke, Frederick L., additional, Gonzalez, Rebecca, additional, Kocoglu, Mehmet H., additional, Sannareddy, Aishwarya, additional, Afrough, Aimaz, additional, McGuirk, Joseph P., additional, Shune, Leyla, additional, Patel, Krina K., additional, and Hansen, Doris K, additional

Published
2023
Full Text
View/download PDF

16. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Author

Afrough, Aimaz, primary, Alsfeld, Leonard C., additional, Milton, Denái R., additional, Delgado, Ruby, additional, Popat, Uday R., additional, Nieto, Yago, additional, Kebriaei, Partow, additional, Oran, Betul, additional, Saini, Neeraj, additional, Srour, Samer, additional, Hosing, Chitra, additional, Cheema, Faisal H., additional, Ahmed, Sairah, additional, Manasanch, Elisabet E., additional, Lee, Hans C., additional, Kaufman, Gregory P., additional, Patel, Krina K., additional, Weber, Donna M., additional, Orlowski, Robert Z., additional, Pinnix, Chelsea C., additional, Dabaja, Bouthaina S., additional, Thomas, Sheeba K., additional, Champlin, Richard E., additional, Shpall, Elizabeth J., additional, Qazilbash, Muzaffar H., additional, and Bashir, Qaiser, additional

Published
2022
Full Text
View/download PDF

17. Treatment Patterns, Outcomes and the Impact of Cellular Therapies in Secondary Central Nervous System Lymphoma (SCNSL): The UT Southwestern Experience

Author

Patel, Akshat Maneesh, primary, Muquith, Maishara, additional, Reves, Heather, additional, Patel, Hetalkumari, additional, Jaso, Jesse, additional, Chen, Weina, additional, Patel, Toral, additional, Desai, Neil, additional, Timmerman, Robert, additional, Kumar, Kiran, additional, Kainthla, Radhika, additional, Afrough, Aimaz, additional, Anderson Jr., Larry D., additional, Chung, Stephen, additional, Madanat, Yazan F., additional, Kaur, Gurbakhash, additional, Kansagra, Ankit, additional, Patel, Prapti, additional, Vusirikala, Madhuri, additional, Collins, Robert H., additional, Sweetenham, John W., additional, Awan, Farrukh T, additional, and Geethakumari, Praveen Ramakrishnan, additional

Published
2022
Full Text
View/download PDF

18. Pre-Lymphodepletion Endothelial Activation and Stress Index As a Predictor of Clinical Outcomes in B-Cell Maturation Antigen CAR T Therapy for Multiple Myeloma

Author

Lee, Jimmy, Upreti, Harsh Vardhan, Sannareddy, Aishwarya, Reves, Heather, Turer, Laura, Abraham, Pearl, Liu, Yulun, Yilmaz, Elif, Wolfe, Heather, Kaur, Gurbakhash, Khan, Adeel, Madanat, Yazan F., Thiebaud, Julio Alvarenga, Velarde, Alejandro Marino, Collins, Robert H., Chung, Stephen, Geethakumari, Praveen Ramakrishnan, Awan, Farrukh T, Anderson, Larry D., Jr., Afrough, Aimaz, and Anderson, Julia Marie

Published
2024
Full Text
View/download PDF

19. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Author

Afrough, Aimaz, primary, Alsfeld, Leonard C., additional, Delgado, Ruby, additional, Popat, Uday, additional, Kebriaei, Partow, additional, Oran, Betul, additional, Saini, Neeraj, additional, Srour, Samer, additional, Hosing, Chitra, additional, Manasanch, Elisabet, additional, Lee, Hans C, additional, Kaufman, Gregory, additional, Patel, Krina K., additional, Orlowski, Robert Z., additional, Pinnix, Chelsea, additional, Dabaja, Bouthaina, additional, Thomas, Sheeba, additional, Weber, Donna, additional, Shpall, Elizabeth J, additional, Champlin, Richard, additional, Qazilbash, Muzaffar H., additional, and Bashir, Qaiser, additional

Published
2021
Full Text
View/download PDF

20. Impact of Induction with VRD Vs. VCD on the Outcome of Patients with Multiple Myeloma after an Autologous Hematopoietic Stem Cell Transplantation

Author

Afrough, Aimaz, primary, Srour, Samer, additional, Bashir, Qaiser, additional, Saini, Neeraj, additional, Hosing, Chitra, additional, Popat, Uday, additional, Kebriaei, Partow, additional, Delgado, Ruby, additional, Murphy, Regan, additional, Manasanch, Elisabet, additional, Lee, Hans C, additional, Kaufman, Gregory, additional, Patel, Krina K., additional, Thomas, Sheeba, additional, Weber, Donna, additional, Orlowski, Robert Z., additional, Shpall, Elizabeth J, additional, Champlin, Richard, additional, and Qazilbash, Muzaffar H., additional

Published
2021
Full Text
View/download PDF

22. 42 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience

Author

Sidana, Surbhi, Peres, Lauren, Hashmi, Hamza, Hosoya, Hitomi, Ferreri, Christopher, Atrash, Shebli, Khouri, Jack, Voorhees, Peter M., Dima, Danai, Simmons, Gary Lee, Kalariya, Nilesh, Hovanky, Vanna, Bharadwaj, Sushma, Arai, Sally, Miklos, David B., Wagner, Charlotte, Davis, James, Sborov, Douglas, Nishihori, Taiga, Alsina, Melissa, Locke, Frederick L., Gonzalez, Rebecca, Kocoglu, Mehmet H., Sannareddy, Aishwarya, Afrough, Aimaz, McGuirk, Joseph P., Shune, Leyla, Patel, Krina K., and Hansen, Doris K

Published
2023
Full Text
View/download PDF

23. 536 - Treatment Patterns, Outcomes and the Impact of Cellular Therapies in Secondary Central Nervous System Lymphoma (SCNSL): The UT Southwestern Experience

Author

Patel, Akshat Maneesh, Muquith, Maishara, Reves, Heather, Patel, Hetalkumari, Jaso, Jesse, Chen, Weina, Patel, Toral, Desai, Neil, Timmerman, Robert, Kumar, Kiran, Kainthla, Radhika, Afrough, Aimaz, Anderson Jr., Larry D., Chung, Stephen, Madanat, Yazan F., Kaur, Gurbakhash, Kansagra, Ankit, Patel, Prapti, Vusirikala, Madhuri, Collins, Robert H., Sweetenham, John W., Awan, Farrukh T, and Geethakumari, Praveen Ramakrishnan

Published
2022
Full Text
View/download PDF

24. 503 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Author

Afrough, Aimaz, Alsfeld, Leonard C., Delgado, Ruby, Popat, Uday, Kebriaei, Partow, Oran, Betul, Saini, Neeraj, Srour, Samer, Hosing, Chitra, Manasanch, Elisabet, Lee, Hans C, Kaufman, Gregory, Patel, Krina K., Orlowski, Robert Z., Pinnix, Chelsea, Dabaja, Bouthaina, Thomas, Sheeba, Weber, Donna, Shpall, Elizabeth J, Champlin, Richard, Qazilbash, Muzaffar H., and Bashir, Qaiser

Published
2021
Full Text
View/download PDF

25. 495 - Impact of Induction with VRD Vs. VCD on the Outcome of Patients with Multiple Myeloma after an Autologous Hematopoietic Stem Cell Transplantation

Author

Afrough, Aimaz, Srour, Samer, Bashir, Qaiser, Saini, Neeraj, Hosing, Chitra, Popat, Uday, Kebriaei, Partow, Delgado, Ruby, Murphy, Regan, Manasanch, Elisabet, Lee, Hans C, Kaufman, Gregory, Patel, Krina K., Thomas, Sheeba, Weber, Donna, Orlowski, Robert Z., Shpall, Elizabeth J, Champlin, Richard, and Qazilbash, Muzaffar H.

Published
2021
Full Text
View/download PDF

26. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.

Author

Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, and Bashir Q

Subjects
Humans, Retrospective Studies, Survival Analysis, Neoplasm Recurrence, Local complications, Chronic Disease, Multiple Myeloma therapy, Hematopoietic Stem Cell Transplantation adverse effects, Graft vs Host Disease epidemiology, Graft vs Host Disease etiology
Abstract

Despite remarkable progress in survival with the availability of novel agents, an overwhelming majority of patients with multiple myeloma (MM) have disease that relapses. Allogeneic (allo-) hematopoietic cell transplantation (HCT) is a potentially curative option for a subgroup of patients with high-risk MM. This study assessed the long-term outcome of MM patients who underwent allo-HCT while in first remission as consolidation treatment. Thirty-three patients with newly diagnosed MM who underwent allo-HCT as part of consolidation therapy between 1994 and 2016 were reviewed retrospectively. Of these patients, 70% underwent autologous HCT before allo-HCT. All patients were chemosensitive and achieved at least partial response before proceeding to allo-HCT. Most received nonmyeloablative/reduced-intensity conditioning (88%) and a matched sibling donor graft (85%). Acute graft-versus-host disease (GVHD) and chronic GVHD occurred in 30% and 61% of patients, respectively. The median duration of follow-up was 64.1 months (range, 1.4 to 199.2 months) for all patients and 164.4 months (range, 56.0 to 199.2 months) for survivors. The median progression-free survival (PFS) was 36 months (95% confidence interval (CI), 8.6 to 73.0 months). The median time from treatment to progression was 73.0 months (95% CI, 30.6 months to not reached). The median overall survival (OS) was 131.9 months (95% CI, 38.4 months to not reached). Of all patients, 39% were alive for more than 10 years, with 46% (n = 6) without progression or relapse. The cumulative incidence of relapse was 18% at 1 year, 39% at 5 years, and 46% at 10 years post-allo-HCT. The cumulative incidence of nonrelapse mortality was 3% at 100 days, 18% at 1 year, 21% at 3 years, and 24% at 5 year post-allo-HCT. On multivariable analysis, high-risk cytogenetics were associated with a shorter PFS (hazard ratio [HR], 2.7; 95% CI, 1.01 to 7.21; P = .047) and OS (HR, 4.91; 95% CI, 1.48 to 16.27; P = .009). Achieving complete remission after allo-HCT also was associated with longer PFS (HR, 0.24; 95% CI, 0.09 to 0.64; P = .004) and OS (HR, .23; 95% CI, .07 to .72; P = .012). Allo-HCT may confer a survival advantage in a selected population of MM patients when performed early in the disease course; additional data on identifying the patients who will benefit the most are needed., (Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results